

- 4  
B
9. (Amended) Isolated DNA encoding the extracellular portion of the HER2 molecule essentially free of transmembrane and intracellular portions of the HER2 molecule and essentially free of DNA encoding a tyrosine kinase domain, said isolated DNA [as defined by claim 1,] terminating upstream of the portion encoding the transmembrane domain of said HER2 molecule.

- 5  
B
12. (Amended) The isolated DNA as defined by claim 9, wherein said DNA encodes an immune epitope [a sequence of at least 9 amino acids] of said extracellular portion [, and none of the transmembrane or intracellular portions of said HER2 molecule.]

- 6  
B
18. (Amended) A process for producing a[n] secreted extracellular portion of the HER2 molecule essentially free of transmembrane and intracellular portions of the HER2 molecule, said process comprising the steps of:
- a) ligating the isolated DNA as defined by claim 9 into an expression vector capable of expressing said isolated DNA in a suitable host;
  - b) transforming said host with said expression vector;
  - c) culturing said host under conditions suitable for expression of said isolated DNA, [and] production of said extracellular portion, and secretion of said extracellular portion; and
  - d) isolating said secreted extracellular portion from said host.

- 7  
B  
c
22. (Amended) A <sup>composition</sup> ~~vaccine~~ comprising the isolated polypeptide [extracellular portion of the HER2 molecule] as defined by claim 26, [1.] <sup>and an adjuvant</sup>

Please cancel claims 1, 4, 6, and 8.

Please add the following new claims: